The incidence and risk factors for ovarian metastasis and overall survival with ovarian preservation for early-stage adenocarcinoma of the cervix-A meta-analysis

Objective: To compare the incidence of ovarian metastasis (OM) in early stage adenocarcinoma (AC) and squamous cell carcinoma (SCC) of the cervix, evaluate the overall survival with ovarian preservation and determine risk factors of OM for early stage AC. Data sources, methods of study selection: We searched the Cochranes database, Embase, and PubMed for publications to November 2020. The articles reporting the incidence, risk factors and overall survival of OM in AC were included. Articles that lacked sufficient data of the odds ratios (ORs) and 95% confidence intervals (CIs) were excluded. A fixed effects model was used to calculate OR and 95% CIs. Eggers test and Funnel plot were used to test the publication bias. Forest plots was used to present and synthesise results. Tabulation, integration and results: In the meta-analysis, the incidence of OM of AC was higher than that of SCC (OR 5.68, 95% CI 4.40–7.32, I2 = 28.1%) in stage IA-IIB. The incidence of OM was 0% in stage IA, 2.72% in stage IB, 5.95% in stage IIA, and 12.86% in stage IIB AC. Ovarian preservation was not significantly associated with OS (OR 0.53, 95% CI 0.35–0.80, I2 = 37.8%) in early stage of AC. We found seven risk factors for OM: deep stromal invasion (OR 8.80, 95% CI 3.20–24.23, I2 = 0%), corpus uteri invasion (OR 6.29, 95% CI 3.36–11.77, I2 = 21.8%), tumor size >$>$4 cm (OR 3.78, 95% CI 1.86–7.69, I2 = 30.5%), FIGO stage IIA (OR 3.67, 95% CI 1.98–6.81, I2 = 0%), FIGO stage IIB (OR 4.31, 95% CI 2.74–6.77, I2 = 0%), FIGO stage II (OR 3.99, 95% CI 2.49–6.41, I2 = 0%) and lympho-vascular space invasion (OR 2.90, 95% CI 1.36–6.17, I2 = 0%). Conclusions: Ovarian preservation is only recommended in stage IA and stage IB AC without risk factors, but not reasonable for stage IIA and IIB AC. Both stage IIA and IIB are risk factors for OM in early stage AC.

Adenocarcinoma of cervix; Ovarian preservation; Ovarian metastasis; Risk factors

[1] Chung HH, Jang MJ, Jung KW, Won YJ, Shin HR, Kim JW, et al. Cervical cancer incidence and survival in Korea: 1993–2002. International Journal of Gynecological Cancer. 2006; 16: 1833–1838.

[2] Smith HO, Tiffany MF, Qualls CR, Key CR, et al. The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States: a 24-year population-based study. Gynecologic Oncology. 2000; 78: 97–105.

[3] Davy MLJ, Dodd TJ, Luke CG, Roder DM, et al. Cervical cancer: effect of glandular cell type on prognosis, treatment, and survival. Obstetrics and Gynecology. 2003; 101: 38–45.

[4] Toki N, Tsukamoto N, Kaku T, Toh N, Saito T, Kamura T, et al. Microscopic ovarian metastasis of the uterine cervical cancer. Gynecologic Oncology. 1991; 41: 46–51.

[5] Yamamoto R, Okamoto K, Yukiharu T, Kaneuchi M, Negishi H, Sakuragi N, et al. A Study of Risk Factors for Ovarian Metastases in Stage IB–IIIB Cervical Carcinoma and Analysis of Ovarian Function after a Transposition. Gynecologic Oncology. 2001; 82: 312–316.

[6] Nakanishi T, Wakai K, Ishikawa H, Nawa A, Suzuki Y, Nakamura S, et al. A Comparison of Ovarian Metastasis between Squamous Cell Carcinoma and Adenocarcinoma of the Uterine Cervix. Gynecologic Oncology. 2001; 82: 504–509.

[7] Shimada M, Kigawa J, Nishimura R, Yamaguchi S, Kuzuya K, Nakanishi T, et al. Ovarian metastasis in carcinoma of the uterine cervix. Gynecologic Oncology. 2006; 101: 234–237.

[8] Kim M, Chung HH, Kim JW, Park N, Song Y, Kang S, et al. Uterine corpus involvement as well as histologic type is an independent predictor of ovarian metastasis in uterine cervical cancer. Journal of Gynecologic Oncology. 2008; 19: 181–184.

[9] Kasamatsu T, Onda T, Sawada M, Kato T, Ikeda S, Sasajima Y, et al. Radical hysterectomy for FIGO stage I–IIB adenocarcinoma of the uterine cervix. British Journal of Cancer. 2009; 100: 1400–1405.

[10] Hu T, Wu L, Xing H, Yang R, Li X, Huang K, et al. Development of Criteria for Ovarian Preservation in Cervical Cancer Patients Treated with Radical Surgery with or without Neoadjuvant Chemotherapy: a Multicenter Retrospective Study and Meta-analysis. Annals of Surgical Oncology. 2013; 20: 881–890.

[11] Sutton GP, Bundy BN, Delgado G, Sevin BU, Creasman WT, Major FJ, et al. Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. American Journal of Obstetrics and Gynecology. 1992; 166: 50–53.

[12] Rocca WA, Grossardt BR, de Andrade M, Malkasian GD, Melton LJ, et al. Survival patterns after oophorectomy in premenopausal women: a population-based cohort study. The Lancet Oncology. 2006; 7: 821–828.

[13] Parker WH, Broder MS, Chang E, Feskanich D, Farquhar C, Liu Z, et al. Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses’ health study. Obstetrics and Gynecology. 2009; 113: 1027–1037.

[14] Landoni F, Zanagnolo V, Lovato-Diaz L, Maneo A, Rossi R, Gad-ducci A, et al. Ovarian metastases in early-stage cervical cancer (IA2-IIA): a multicenter retrospective study of 1965 patients (a Cooperative Task Force study). International Journal of Gynecological Cancer. 2007; 17: 623–628.

[15] Matsuo K, Shimada M, Yamaguchi S, Kanao H, Nakanishi T, Saito T, et al. Identifying a candidate population for ovarian conservation in young women with clinical stage IB-IIB cervical cancer. International Journal of Cancer. 2018; 142: 1022–1032.

[16] Cao L, Wen H, Feng Z, Han X, Wu X, et al. Distinctive clinicopathologic characteristics and prognosis for different histologic subtypes of early cervical cancer. International Journal of Gynecologic Cancer. 2019; 29: 1244–1251.

[17] Hopkins MP, Sutton P, Roberts JA. Prognostic features and treatment of endocervical adenocarcinoma of the cervix. Gynecologic Oncology. 1987; 27: 69–75.

[18] Lyu J, Sun T, Tan X. Ovarian preservation in young patients with stage I cervical adenocarcinoma: a surveillance, epidemiology, and end results study. International Journal of Gynecological Cancer. 2014; 24: 1513–1520.

[19] Chen J, Wang R, Zhang B, Lin X, Wei J, Jia Y, et al. Safety of ovarian preservation in women with stage i and II cervical adenocarcinoma: a retrospective study and meta-analysis. American Journal of Obstetrics and Gynecology. 2016; 215: 460.e1–460.e13.

[20] Hu J, Jiao X, Yang Z, Cui H, Guo H, Wu Y, et al. Should ovaries be removed or not in early-stage cervical adenocarcinoma: a multi-center retrospective study of 105 patients. Journal of Obstetrics and Gynaecology. 2017; 37: 1065–1069.

[21] Xie X, Song K, Cui B, Jiang J, Yang X, Kong B, et al. A comparison of the prognosis between adenocarcinoma and squamous cell carcinoma in stage IB-IIA cervical cancer. International Journal of Clinical Oncology. 2018; 23: 522–531.

[22] Xu H, Tang X, Ding J, Qiu J, Zhang X, Hua K, et al. Ovarian conservation is associated with better survival in young patients with T1N0M0 cervical adenocarcinoma: a population-based study. Archives of Gynecology and Obstetrics. 2018; 297: 775–784.

[23] Natsume N, Aoki Y, Kase H, Kashima K, Sugaya S, Tanaka K, et al. Ovarian metastasis in stage IB and II cervical adenocarcinoma. Gynecologic Oncology. 1999; 74: 255–258.

[24] Zhou J, Chen Y, Zhang P, Lou H. Ovarian preservation in adeno-carcinoma of the uterine cervix. Journal of Ovarian Research. 2017; 10: 48.

[25] Lu H, Li J, Wang L, Zhou H, Liu Y, Wang D, et al. Is Ovarian Preservation Feasible in Early-Stage Adenocarcinoma of the Cervix? Medical Science Monitor. 2016; 22: 408–414.

[26] Tabata M, Ichinoe K, Sakuragi N, Shiina Y, Yamaguchi T, Mabuchi Y, et al. Incidence of ovarian metastasis in patients with cancer of the uterine cervix. Gynecologic Oncology. 1987; 28: 255–261.

[27] Cheng HY, Huo LQ, Zong LJ, Kong Y, Yang J, Xiang Y, et al. Oncological Outcomes and Safety of Ovarian Preservation for Early Stage Adenocarcinoma of Cervix: a Systematic Review and Meta-Analysis. Frontiers in Oncology. 2019; 9: 777.

[28] Touhami O, Plante M. Should ovaries be removed or not in (early-stage) adenocarcinoma of the uterine cervix: A review. Gynecologic Oncology. 2015; 136: 384–388.

[29] Nadeem R, Catheryn M, Sarah B, Kristin B, Susana MC, Hye SC, et al. NCCN Clinical Practice Guidelines in Oncology Cervical Cancer Version 1. 2021. Available at: https://www.nccn.org/home (Accessed: 27 November 2021).